| |
| |
| |
Centre for Policy on Ageing | |
 | |
|
Reaching the population with dementia drugs
— what are the challenges? | | Author(s) | Fiona E Matthews, Ian McKeith, John Bond |
| Corporate Author | Medical Research Council Cognitive Function and Ageing Study (MRC CFAS) |
| Journal title | International Journal of Geriatric Psychiatry, vol 22, no 7, July 2007 |
| Pages | pp 627-631 |
| Source | http://www.interscience.wiley.com |
| Keywords | Dementia ; Drugs ; Usage [services] ; Longitudinal surveys. |
| Annotation | Systematic evidence became available in the late 1990s on the efficacy of cholinesterase inhibitors (CHEIs) for patients with mild to moderate Alzheimer's disease (AD) and they began to be used sporadically. Since January 2000, the UK based (National Institute for Health and Clinical Excellence (NICE) guidelines indicated that one of three CHEIs could be prescribed for these patients. Since then, the cost of prescription in England and Wales has risen. The Medical Research Council Cognitive Function and Ageing Study (MRC CFAS) has used data from a 10-year follow-up and later 12 year interview with people originally aged 65+ to investigate who was taking CHEIs during the period 2001-2004. Only 12 of the 219 individuals who received a study diagnosis of dementia were prescribed CHEIs (5%) in 2001/2003, and none of the 28 individuals with a study diagnosis of dementia in 2004 were prescribed CHEIs. Uptake was biased towards individuals with more education and higher social class. These data suggest that any impact on AD progression at the population level will be negligible as prescription of CHEIs and uptake in the age group at highest risk is so limited. There is little evidence that this as changed over time. (RH). |
| Accession Number | CPA-071113205 A |
| Classmark | EA: LLD: QLD: 3J |
Data © Centre for Policy on Ageing |
|
| ...from the Ageinfo database published by Centre for Policy on Ageing. |
| |
|
|